Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis

被引：136

作者：

Dev, Kumlesh K. ^{[1
,2
]}

Mullershausen, Florian ^{[3
]}

Mattes, Henri ^{[2
]}

Kuhn, Rainer R. ^{[2
]}

Bilbe, Graeme ^{[2
]}

Hoyer, Daniel ^{[2
]}

Mir, Anis ^{[2
]}

机构：

[1] Natl Univ Ireland Univ Coll Cork, Dept Anat & Neurosci, Cork, Ireland

[2] Nova Pharmaceut, Novartis Inst BioMed Res, Dept Neurosci, Basel, Switzerland

[3] Nova Pharmaceut, Novartis Inst BioMed Res, Dept G Prot Coupled Receptors, Basel, Switzerland

来源：

PHARMACOLOGY & THERAPEUTICS | 2008年 / 117卷 / 01期

关键词：

sphingosine-1-phosphate; SIP receptor; FTY720 (fingolimod); central nervous system; multiple sclerosis;

D O I：

10.1016/j.pharmthera.2007.08.005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Multiple sclerosis (MS) is an autoimmune, neurological disability with unknown etiology. The current therapies available for MS work by all immunomodulatory action, preventing T-cell- and macrophage-mediated destruction of brain-resident oligodendrocytes and axonal loss. Recently, FTY720 (fingolimod) was shown to significantly reduce relapse rates in MS patients and is currently in Phase III clinical trials. This drug attenuates trafficking of harmful T cells entering the brain by regulating sphingosine-1-phosphate (SIP) receptors. Here, we outline the direct roles that S I P receptors play in the central nervous system (CNS) and discuss additional modalities by which FTY720 may provide direct neuroprotection in MS. (c) 2007 Elsevier Inc. All rights reserved.

引用

页码：77 / 93

页数：17

共 50 条

[41] The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration
Anastasiadou, Sofia
Knoell, Bernd
EXPERIMENTAL NEUROLOGY, 2016, 279 : 243 - 260
[42] Sphingosine-1-phosphate receptor modulators in stroke treatment
Zhang, Wanzhou
Li, Yudi
Li, Fangming
Ling, Li
JOURNAL OF NEUROCHEMISTRY, 2022, 162 (05) : 390 - 403
[43] Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis
Chiba, Kenji
Kataoka, Hirotoshi
Seki, Noriyasu
Shimano, Kyoko
Koyama, Mamoru
Fukunari, Atsushi
Sugahara, Kunio
Sugita, Takahisa
INTERNATIONAL IMMUNOPHARMACOLOGY, 2011, 11 (03) : 366 - 372
[44] FTY720 Story. Its Discovery and the Following Accelerated Development of Sphingosine 1-Phosphate Receptor Agonists as Immunomodulators Based on Reverse Pharmacology
Adachi, Kunitomo
Chiba, Kenji
PERSPECTIVES IN MEDICINAL CHEMISTRY, 2007, 1 : 11 - 23
[45] Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors
Osinde, Maribel
Mullershausen, Florian
Dev, Kumlesh K.
NEUROPHARMACOLOGY, 2007, 52 (05) : 1210 - 1218
[46] Differential Tolerance to FTY720-Induced Antinociception in Acute Thermal and Nerve Injury Mouse Pain Models: Role of Sphingosine-1-Phosphate Receptor Adaptation
Sim-Selley, Laura J.
Wilkerson, Jenny L.
Burston, James J.
Hauser, Kurt F.
McLane, Virginia
Welch, Sandra P.
Lichtman, Aron H.
Selley, Dana E.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2018, 366 (03): : 509 - 518
[47] Sphingosine 1-Phosphate Receptor 1 and 3 Are Upregulated in Multiple Sclerosis Lesions
Van Doorn, Ruben
Van Horssen, Jack
Verzijl, Dennis
Witte, Maarten
Ronken, Eric
Hof, Bert Van Het
Lakeman, Kim
Dijkstra, Christine D.
Van der Valk, Paul
Reijerkerk, Arie
Alewijnse, Astrid E.
Peters, Stephan L. M.
De Vries, Helga E.
GLIA, 2010, 58 (12) : 1465 - 1476
[48] Sphingosine 1-phosphate signaling in astrocytes: Implications for progressive multiple sclerosis
Farez, Mauricio F.
Correale, Jorge
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 361 : 60 - 65
[49] Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis
Roy, Reshmi
Alotaibi, Alaa A.
Freedman, Mark S.
CNS DRUGS, 2021, 35 (04) : 385 - 402
[50] Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis
Adnan M. Subei
Jeffrey A. Cohen
CNS Drugs, 2015, 29 : 565 - 575

← 1 2 3 4 5 →